Merrill Lynch Takes Bullish Stance on Cannabis Testing Industry


Spencer Schredder

December 17th, 2015

News, Top News


 Bank of America Merrill Lynch recently released a new biotechnology report focused on medical cannabis called “Medical cannabis has high POTential: a joint biotech & tools primer”. In the report, the analyst takes a detailed look at the current medical marijuana landscape and the various companies operating within it, while being bullish on the overall cannabis testing market and the growth prospects for tools within it.

The report mentions a number of cannabis testing companies:

“Cannabis testing market in the US consists primarily of small providers of testing and consulting services. Some of the leading cannabis testing and consulting services providers include: Steep Hill Labs, CannLabs (OTC: CANL), DigiPath (OTC: DIGP), Signal Bay (OTC: SGBY), The Werc Shop, and Green Standards Diagnostics. Due to rapidly evolving and potentially conflicting legislation enacted on a state by state basis, the cannabis testing industry is subject to disruptive changes. Competition is based on price, regulatory compliance, vendor relationships, and ease of use of services.”

And, indicates that the firm is bullish on the industry’s prospects:

“The cannabis industry is poised for growth if cannabis legalization and use expand. As the cannabis industry expands, we expect to see a corresponding increase in cannabis medical research and the implementation of cannabis testing and labeling regulations, which should drive adoption and growth of life sciences tools within this market in our view.

“While progress has been slow and much work remains to be done on the set up and implementation of a standard regulatory framework for the testing of cannabis products, there have been some recent steps in the right direction. In September 2015, California House passed a bill (California bill AB 266) that mandates the lab testing of all medical cannabis for regulatory purposes on or before July 1, 2017 and we expect other states where cannabis has been legalized in some form to follow. Many stakeholders in the cannabis industry are also showing support for regulatory testing requirements in order to ensure a safe access to cannabis.”

DigiPath Inc. (OTCQB: DIGP), a leading cannabis testing provider with a flagship laboratory in Nevada, believes that the report is spot-on with its analysis.

“This analysis confirms what our own research has found, and what we’ve built our business model around: the legal cannabis sector is growing rapidly, and the demand for cannabis testing facilities will only increase as more states implement strict safety standards,” notes Todd Denkin, CEO and president of Digipath Inc. and Digipath labs.

According to the report, medical cannabis is already a $2.9 billion business and could double, while the cannabis testing sector is estimated to reach $800-900 million by 2020.

“When we designed the DigiPath Labs flagship location outside Las Vegas, we set out to create the testing lab of the future. We combined the finest instrumentation on the market with exacting testing procedures to ensure that we will always be ahead of regulators,” said Mr. Denkin. “This report is yet another validation of our strategy.”

Shares of DigiPath Inc. opened 10% higher during today’s trading.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Spencer Schredder

Mr. Shredder has over a decade of experience in the financial markets as both a private investor and financial journalist.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.



Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading